Facebook
Twitter
LinkedIn
ForwardCombined Modality Therapy for Lymph Node Positive Prostate Cancer
Historically, the management of lymph node positive prostate cancer was limited to androgen deprivation therapy, but increasing data now support the use of multimodality therapy. As treatment options have expanded, patient-centered decision making has become increasingly complicated. Education is needed to help clinicians provide patients with the most up-to-date information regarding the impact of various management strategies on treatment efficacy and quality of life.
This course involves case-based presentations with expert speakers to review the various treatment options for lymph node positive prostate cancer, including radical prostatectomy, androgen deprivation therapy, and external beam radiotherapy. The role of the radiation oncologist in the workup of patients with node-positive prostate cancer is reviewed (including PSMA PET scans), along with a discussion on optimizing patient selection and treatment techniques. Post-operative management of patients with pathologic lymph node positive disease is reviewed in detail, as well as the concurrent use of systemic and radiation therapy for patients with clinically staged N1 disease. Each therapeutic modality will be discussed in the context of recently published data, ongoing clinical trials, and future directions, with a patient-centered focus.
Topics:
- Introduction and Case Presentation
Rahul D. Tendulkar, MD, FASTRO - Post-Operative Therapy for Pathologic Node Positive Prostate Cancer
Leslie K. Ballas, MD - Optimizing Multimodality Therapy for Clinically Node Positive Prostate Cancer
Omar Y. Mian, MD, PhD - Modern Systemic Therapy for Advanced Prostate Cancer
Hala Borno, MD - Q and A
Full Panel
This activity is available from May 14, 2024, through 11:59 p.m. Eastern time on May 13, 2026.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, radiation therapists, dosimetrists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the workup and treatment options for lymph node positive prostate cancer.
- Explain the impact of multimodality treatment on patient quality of life.
- Identify opportunities to enhance systemic therapy in node positive prostate cancer.
- Rahul D. Tendulkar, MD, FASTRO, is employed by the Cleveland Clinic Foundation. He receives honoraria from Varian Medical Systems.
- Leslie K. Ballas, MD, is employed by Cedars-Sinai Medical Center. Dr. Ballas previously served on advisory boards with Pfizer and Blue Earth Diagnostics. Dr. Ballas is an editor for UroToday.
- Omar Y. Mian, MD, PhD, is employed by the Cleveland Clinic. Dr. Mian receives compensation from Bayer, honoraria from Blue Earth Diagnostics, and receives grant/research funding from Varian, Gilead, PathomIQ, and NCCN. He serves in an uncompensated role with Veracyte, Inc.
- Hala Borno, MD, is employed by University of California, San Francisco and Trial Library, Inc. Dr. Borno is Founder and CEO of Trial Library, Inc.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until May 13, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.